AngioDynamics, Inc. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended November 30, 2007, and the six-month period ended on that date. AngioDynamics, Inc. is a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease and local oncology therapy. The company operates as a single segment focused on the manufacture and sale of medical devices. A significant event during this period was the consolidation of results from the acquisition of RITA Medical Systems, Inc., completed on January 29, 2007.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2007 | Six Months Ended Nov 30, 2007 |
|---|---|---|
| Net Sales | $41.5 million | $79.0 million |
| Gross Profit | $25.5 million (61.3% margin) | $48.0 million (60.7% margin) |
| Operating Income | $4.8 million | $8.3 million |
| Net Income | $3.1 million | $5.5 million |
| Diluted EPS | $0.13 | $0.23 |
| Cash from Operations | N/A | $10.3 million |
| Total Cash & Equivalents | $79.6 million (including $11.2 million restricted cash) | |
| Total Debt | $17.3 million ($10.0 million current, $7.2 million long-term) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 70% ($17.1 million) for the quarter and 77% ($34.4 million) for the six months compared to the prior year periods. This growth is primarily attributable to the inclusion of RITA Medical Systems products.
- Profitability: Gross profit margins improved to 61.3% (quarter) and 60.7% (six months) from 58.5% and 58.6% respectively in the prior year, driven by a favorable product mix from higher-margin RITA products.
- Operating Expenses: Operating expenses increased significantly due to the RITA acquisition. Amortization of purchased intangibles rose to $1.6 million for the quarter (from $0.1 million) and $3.2 million for the six months (from $0.1 million). R&D and Sales & Marketing expenses also increased due to added personnel and territories.
- Litigation Provision: A current liability of $10.0 million was recorded for a patent infringement judgment against Diomed, Inc., including interest. This amount is backed by restricted cash.
Outlook, Risks, and Contingencies
- Guidance: Management expects R&D expenditures to remain in the range of 8% to 9% of net sales for fiscal 2008. No specific revenue guidance was provided in this text.
- Acquisition Contingency: The company has a pending acquisition of Oncobionic, Inc., subject to successful human use tests for irreversible electroporation technology. Results are expected within six months. A $5.0 million non-refundable deposit has been paid.
- Litigation Risks:
- Diomed v. AngioDynamics: The company is appealing a $9.71 million judgment. An injunction prohibits the sale of original bare fiber VenaCure kits; the company has transitioned to new NeverTouch kits.
- VNUS Medical Technologies: A patent infringement suit is pending with a potential loss range of $0 to $10 million. Trial is anticipated in 2008.
- Indemnification Dispute: The company filed an action against biolitec to enforce indemnification obligations regarding the Diomed litigation.
- Liquidity: Management believes current cash and investment balances, combined with operating cash flow, are sufficient for the next 12 months. However, significant future acquisitions may require additional financing.
Investor Verification Checklist
- Verify the status and potential outcome of the appeal in Diomed v. AngioDynamics and the associated $10 million liability.
- Monitor the results of the Oncobionic human use tests, which are a condition precedent for the $25 million acquisition closing.
- Assess the impact of the $1.6 million quarterly amortization expense on future earnings as RITA intangibles continue to be amortized.
- Review the company's ability to maintain gross margins as new product lines (e.g., NeverTouch) scale and older products face litigation restrictions.
- Confirm the status of the indemnification claim against biolitec regarding defense costs for the Diomed litigation.